Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
H Hua, Q Kong, J Yin, J Zhang, Y Jiang - Journal of hematology & …, 2020 - Springer
… growth factor (HGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF),
and insulin-like growth factor … and invasion thereby promoting tumor growth, angiogenesis, …
and insulin-like growth factor … and invasion thereby promoting tumor growth, angiogenesis, …
[HTML][HTML] Tumor angiogenesis: Current challenges and therapeutic opportunities
FH Al-Ostoot, S Salah, HA Khamees… - Cancer Treatment and …, 2021 - Elsevier
… of oxygen, nutrients, and growth factors as well as tumor dissemination to distant organs. …
solid tumors that depend on cutting or at least reducing the blood supply to tumor micro-…
solid tumors that depend on cutting or at least reducing the blood supply to tumor micro-…
CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target
L Li, L Zhong, C Tang, L Gan, T Mo, J Na, J He… - Clinical and …, 2022 - Springer
… therapies [5]. Anti-angiogenic therapies targeting the vascular endothelial growth factor (…
angiogenesis therapy [7] and tumor prevention based on its expression in blood vessels [8]. …
angiogenesis therapy [7] and tumor prevention based on its expression in blood vessels [8]. …
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
R Tamura, T Tanaka, Y Akasaki, Y Murayama… - Medical Oncology, 2020 - Springer
… Vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis … factor
and its receptor [29]. TAMs induce various growth factors such as basic fibroblast growth factor, …
and its receptor [29]. TAMs induce various growth factors such as basic fibroblast growth factor, …
Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts
X Shi, CD Young, H Zhou, XJ Wang - Biomolecules, 2020 - mdpi.com
… Higher self-renewal ability (stemness) of CSCs, which means more CSCs in the tumor,
indicates a higher possibility of anti-tumor therapy resistance. CAF-secreted TGF-β2 activated …
indicates a higher possibility of anti-tumor therapy resistance. CAF-secreted TGF-β2 activated …
[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E Martinelli, D Ciardiello, G Martini, T Troiani… - Annals of …, 2020 - Elsevier
… be associated with increased levels of vascular endothelial growth factor and that inhibiting
angiogenesis could contribute to tumor growth inhibition. Under the selective pressure of …
angiogenesis could contribute to tumor growth inhibition. Under the selective pressure of …
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
ZL Liu, HH Chen, LL Zheng, LP Sun… - … and targeted therapy, 2023 - nature.com
… maintain the tumor growth. A … tumor tissue, which releases abundant growth factors and
cytokines, stimulating angiogenesis and lymphangiogenesis to meet the needs of tumor growth …
cytokines, stimulating angiogenesis and lymphangiogenesis to meet the needs of tumor growth …
Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target
… the majority of tumor cells in human malignant tumors [9, 22] and this will be the highlighted
topic of the current review. As mentioned, MDK functions as a cytokine and growth factor with …
topic of the current review. As mentioned, MDK functions as a cytokine and growth factor with …
YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy
BJ Thompson - Bioessays, 2020 - Wiley Online Library
… and tumor suppressors that primarily affect a handful of signal transduction pathways, most
importantly the growth factor … targeted therapeutics against growth factor signaling have had …
importantly the growth factor … targeted therapeutics against growth factor signaling have had …
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
… CAR T cells in solid tumors. Given that Flt3L is a critical growth factor for DCs 6 , we hypothesized
that armored T cells engineered to secrete Flt3L can overcome tumor heterogeneity by …
that armored T cells engineered to secrete Flt3L can overcome tumor heterogeneity by …
相关搜索
- cancer therapy growth factor receptor
- vascular endothelial growth factor
- adoptive cellular therapy cell growth factor
- cancer therapy growth factor network
- growth factor therapeutic perspectives
- tumor microenvironment growth factor β
- growth factor promising therapeutic target
- anti-epidermal growth factor receptor inhibitors
- growth factor therapy in colorectal cancer
- growth factor system
- growth factor igf cancer drug resistance
- transforming growth factor
- growth factor 1 compensatory insulin receptor
- anti-epidermal growth factor receptor egfr therapy
- targeted therapy growth factor receptor
- growth factor immunosuppressive tumor microenvironment